AAA817 with hormone therapy for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new combination treatment (AAA817 plus a hormone therapy) against standard care for men with advanced PSMA-positive prostate cancer that has spread and stopped responding to a previous hormone therapy. It may be an option if you haven't had certain prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have prostate cancer that has spread to other parts of the body and it is PSMA-positive (a special scan shows a protein called PSMA on your cancer cells)
- Your cancer got worse while you were on a hormone therapy (like enzalutamide or abiraterone)
- You have not had chemotherapy with a taxane (like docetaxel) for advanced prostate cancer that has spread
- You have not had any prior radioactive drug treatment (like Lutathera or Xofigo) for your cancer
- You have not taken a PARP inhibitor (like olaparib) for advanced prostate cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (AAA817) against the usual treatments for men with advanced prostate cancer that has stopped responding to a type of targeted radiation therapy (Lu-PSMA). The goal is to see if the new drug can slow the cancer's growth better than standard options.
This study tests different ways of giving hormone therapy to find the right dose for men with prostate cancer that has spread. It aims to help manage the disease while limiting side effects.
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
This Phase 1 trial tests a small-molecule treatment that carries radioactive material to help treat prostate cancer that has spread and keeps growing despite standard hormone-blocking treatment. It’s mainly looking to find a safe dose and see how well the approach works in people with limited treatment options.
This study looks back at the experiences of men with prostate cancer that has spread to other parts of the body. It aims to learn which treatments—such as hormone therapy combined with other drugs, or a radioactive therapy—work best for different types of advanced prostate cancer.
This trial tests a new way to plan prostate cancer treatment using artificial intelligence and advanced imaging. It’s for people with high-risk prostate cancer that hasn’t spread to lymph nodes or other parts of the body, and who have not had prior radiation to the prostate.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.